Numerous studies have shown that PP2A loss-of-function predict shorter survival independently from other prognostic factors in myeloid and lymphoid malignancies, and disease progression/TKI response in CML. The gene discussed is PTPA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.